TrialJournal of inherited metabolic disease2026

Results From a Phase 2, Open-Label Study Evaluating the Safety, Tolerability, and Effect on Ataxia of GLM101 in Three Adult Patients With PMM2-CDG.

Mercedes Serrano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.